Glenmark Pharmaceuticals Ltd
Please find attached Press Release and Management Discussion & Analysis for the first quarter ended June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 31 Jul 2026, 07:12 PM IST · BSE ID: 50ceb0cc-ec34-4450-b331-5a7b13481b80
View Original BSE Filing (PDF)
💡
In Simple Terms
Glenmark Pharma's first quarter sales and profits increased significantly across India, North America, and other markets.
🤖 AI Summary
- Glenmark Pharmaceuticals' consolidated revenue was Rs. 40,185 million for Q1 FY27, increasing 23.1% YoY.
- India Formulations revenue grew by 15.5% YoY, reaching Rs. 14,321 million in the quarter.
- North America revenue rose 41.1% YoY to Rs. 10,974 million, including deferred out-licensing income recognition.
- EBITDA for Q1 FY27 was Rs. 8,048 million, marking a 38.6% YoY growth with a 20.03% margin.
- Profit After Tax stood at Rs. 4,828 million in Q1 FY27, with a PAT margin of 11.8%.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue
Rs. 40,185 million
23.1%
EBITDA
Rs. 8,048 million
38.6%
Profit After Tax (PAT)
Rs. 4,828 million
India Formulations Revenue
Rs. 14,321 million
15.5%
North America Revenue
Rs. 10,974 million
41.1%
Europe Revenue
Rs. 7,472 million
11.9%
Emerging Markets Revenue
Rs. 7,304 million
27.7%
🏢 How This Affects the Company
The company reported broad-based growth across key markets, with India outperforming the IPM and North America showing robust underlying growth, enhancing its diversified global business position. New product launches in North America, including 9 generic products, and progress with specialty brands like RYALTRIS® and WINLEVI® contribute to business expansion.
Consolidated revenue increased by Rs. 7,541 million YoY to Rs. 40,185 million, while EBITDA grew by Rs. 2,243 million YoY to Rs. 8,048 million. Profit After Tax was Rs. 4,828 million, indicating improved profitability and margin expansion.
Glenmark's injectable manufacturing facility in Monroe, North Carolina received an EIR from U.S. FDA with a VAI classification, leading to the re-launch of Fulvestrant Injection, supporting manufacturing operations. The company also initiated end-to-end commercialization for RYALTRIS® in the USA.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company reported a 23.1% YoY increase in consolidated revenue to Rs. 40,185 million for Q1 FY27, and Profit After Tax of Rs. 4,828 million.
🔍
Management Signal
Management is focused on strengthening core businesses while expanding differentiated specialty and innovation-led platforms for sustainable, profitable growth.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — evaluate sustained growth in North America and India.
Regulatory approvals — monitor new ANDA approvals from US FDA pipeline.
Specialty product sales — track global uptake of RYALTRIS® and WINLEVI®.
LOW RISK
Filing reports positive financial results with no new risks identified.
💡 Investor Takeaway
Glenmark Pharmaceuticals reported Q1 FY27 consolidated revenue of Rs. 40,185 million, a 23.1% YoY increase from Rs. 32,644 million. Profit After Tax was Rs. 4,828 million with an 11.8% margin, compared to Rs. 3,558 million in the prior year period. EBITDA grew 38.6% to Rs. 8,048 million.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated revenue grew 23.1% YoY to Rs. 40,185 million in Q1 FY27, driven by strong performance across key regions.
- EBITDA increased 38.6% YoY to Rs. 8,048 million, achieving a 20.03% margin, reflecting enhanced operational efficiency.
❓ Frequently Asked Questions
What was Glenmark Pharmaceuticals' consolidated revenue in Q1 FY27?
Glenmark Pharmaceuticals reported consolidated revenue of Rs. 40,185 million for the first quarter ended June 30, 2026.
How much did Glenmark Pharmaceuticals' Profit After Tax increase in Q1 FY27?
Glenmark Pharmaceuticals reported Profit After Tax of Rs. 4,828 million in Q1 FY27, with a PAT margin of 11.8%.
What was the growth in Glenmark's India Formulations revenue for Q1 FY27?
Sales from Glenmark's India Formulations business grew by 15.5% YoY to Rs. 14,321 million in Q1 FY27.
What was the EBITDA for Glenmark Pharmaceuticals in Q1 FY27?
Glenmark Pharmaceuticals reported an EBITDA of Rs. 8,048 million in Q1 FY27, showing a 38.6% YoY growth.
What was the YoY growth for Glenmark's North America revenue in Q1 FY27?
North America revenue grew by 41.1% YoY to Rs. 10,974 million in Q1 FY27, which includes deferred out-licensing income recognition.
Questions based on this BSE filing only. For information purposes.